Recombinant human transforming growth factor β1

Manufactured by R&D Systems

Sourced in United Kingdom

Recombinant human transforming growth factor-β1 is a protein produced in a laboratory setting. It is a member of the transforming growth factor beta family. The core function of this protein is to regulate cell growth and differentiation.

Automatically generated - may contain errors

Lab products found in correlation

Dexamethasone (dex), by Merck Group (2 mentions) Transferin, by Merck Group (1 mentions) Insulin, by Merck Group (1 mentions) Vitamin c, by Merck Group (1 mentions) Insulin transferrin selenium, by Merck Group (1 mentions) Sodium pyruvate, by Thermo Fisher Scientific (1 mentions) Insulin like growth factor 1 igf 1, by Merck Group (1 mentions) Dmem f12, by Thermo Fisher Scientific (1 mentions) Amphotericin, by Thermo Fisher Scientific (1 mentions) Glyceraldehyde 3 phosphate dehydrogenase gapdh, by Cell Signaling Technology (1 mentions) Glutamine, by Lonza (1 mentions) Pen strep, by Lonza (1 mentions) Dulbecco s modified eagle s medium, by Lonza (1 mentions)

Close spelling variants of this product

Transforming growth factor-β1 (23 citations)

4 protocols using recombinant human transforming growth factor β1

Chondrogenic Differentiation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

For cartilage cells differentiation, the media contained high-glucose DMEM (4.5 g/mL) supplemented with 10 mol/L dexamethasone (Sigma, St. Louis, MO, USA), 10 ng/mL recombinant human transforming growth factor-β1 (R&D, Valais, Switzerland), 6.25 μg/mL insulin (Sigma, St. Louis, MO, USA), 6.25 μg/mL transferin (Sigma, St. Louis, MO, USA), 50 mg/mL vitamin C (Sigma, St. Louis, MO, USA), 100 ng/mL insulin-like growth factor (Biovision, Milpitas, CA, USA), and 5% FBS or 5% CBS, l-DMEM medium. Differentiation medium was replaced every three days. After three weeks, the cells were fixed with 4% formalin and immunocytochemistry was carried out using mouse anti-human collagen (1:100; Boster, Wuhan, China) according to the instructions of manufacturer.

Du L., Yu Y., Ma H., Lu X., Ma L., Jin Y, & Zhang H. (2014). Hypoxia Enhances Protective Effect of Placental-Derived Mesenchymal Stem Cells on Damaged Intestinal Epithelial Cells by Promoting Secretion of Insulin-Like Growth Factor-1. International Journal of Molecular Sciences, 15(2), 1983-2002.

+ Open protocol

+ Expand

Chondrogenic Differentiation of Bovine BMSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bovine BMSCs were isolated and seeded into 2% alginate hydrogel beads at 20 × 10⁶ cells/mL density, similar to the culture of chondrocytes (Ng et al., 2007 (link)). The beads were placed in chondrogenic culture medium containing high-glucose DMEM supplemented with 1% Insulin-Transferrin-Selenium (Sigma-Aldrich, St. Louis, MO), 100 nM dexamethasone (Sigma-Aldrich) and 10 ng/mL recombinant human transforming growth factor-β1 (R&D System, Minneapolis, MN) (Connelly et al., 2008 (link)). Culture medium was replaced every other day. Groups of BMSCs with their neo-matrices were released from the alginate beads on days 7, 14, and 21 and maintained in high-glucose DMEM for subsequent measurements.

Lee B., Han L., Frank E.H., Grodzinsky A.J, & Ortiz C. (2014). Dynamic Nanomechanics of Individual Bone Marrow Stromal Cells and Cell-Matrix Composites during Chondrogenic Differentiation. Journal of biomechanics, 48(1), 171-175.

+ Open protocol

+ Expand

Chondrogenic Differentiation Protocol

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

For chondrogenic differentiation, 1 × 10⁶ cells were imbedded in 100 µL alginate.^{15 (link)} Chondrogenic differentiation was induced by DMEM/F12 (Gibco) supplemented with 2.8 g/L glucose, 1 mM sodium pyruvate (Gibco), 0.1 mM ascorbic acid-2-phosphate, 0.1 µM dexamethasone, 1% ITS (insulin 25 µg/mL, transferrin 25 µg/mL, and sodium selenite 25 ng/mL), 1.25 mg/mL human serum albumin (Octapharma, Jessheim, Norway), 500 ng/mL bone morphogenic protein-2 (Wyeth Pharmaceuticals, Taplow, UK), 25 ng/mL recombinant human transforming growth factor-β1 (R&D Systems, Minneapolis, MN, USA), and 200 mg/mL insulin-like growth factor 1 (IGF1; Sigma–Aldrich, St. Louis, MO, USA). Medium was changed every 3–4 days. Cells were harvested after 21 days of culture for use in qRT-PCR. The qRT-PCR was done for SOX9, COL2A1, and ACAN (Table 1).

Pullisaar H., Verket A., Szoke K., Tiainen H., Haugen H.J., Brinchmann J.E., Reseland J.E, & Østrup E. (2015). Alginate hydrogel enriched with enamel matrix derivative to target osteogenic cell differentiation in TiO2 scaffolds. Journal of Tissue Engineering, 6, 2041731415575870.

+ Open protocol

+ Expand

Cell Culture Media Components

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dulbecco’s modified Eagle's medium, glutamine, and Pen-Strep (10,000 U/ml) were obtained from Lonza (Verviers, Belgium). Amphotericin was purchased from Life Technologies (Carlsbad, CA). Recombinant human transforming growth factor-β1 was obtained from R&D Systems Europe, Ltd (Abingdon, England). [6-³H] thymidine (20-30 Ci/mmol) was purchased from PerkinElmer (Boston, MA). Antibodies against IL-1R1 were obtained from Millipore (Billerica, MA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was obtained from Cell Signaling Technology (Boston, MA). Secondary antibodies were purchased from Bio-Rad Laboratories (Hercules, CA), LI-COR Biosciences (Lincoln, NE), and Jackson Immunoresearch (Baltimore, PA).

Tjomsland V., Pomianowska E., Aasrum M., Sandnes D., Verbeke C.S, & Gladhaug I.P. (2016). Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic Cancer Cells. Neoplasia (New York, N.Y.), 18(7), 447-456.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!